Drug Profile


Alternative Names: AMG-531; Nplate; Romiplate

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator Kirin-Amgen
  • Developer Amgen; Kirin-Amgen
  • Class Carrier proteins; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Thrombopoietin receptor agonists; Thrombopoietin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Immune thrombocytopenic purpura
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Immune thrombocytopenic purpura
  • Phase II/III Aplastic anaemia
  • Phase II Thrombocytopenia
  • Discontinued Myelodysplastic syndromes

Most Recent Events

  • 03 Dec 2016 Interim adverse events and efficacy data from a phase II trial in Aplastic anaemia presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem - 2016)
  • 01 May 2016 Phase-II/III clinical trials in Aplastic anaemia (Treatment-resistant) in South Korea and Japan (SC) (NCT02773290)
  • 19 Apr 2016 Registered for Immune thrombocytopenic purpura in Venezuela, Peru, Lebanon, Egypt, Macau, Ecuador, Morocco, Guatemala, Brazil, South Africa, Kuwait, Colombia, Serbia (SC) before April 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top